Latrophilin 3, a Gene Involved in Attention Deficit Hyperactivity Disorder
Posted Feb 28 2007 4:00pm
Description of Invention: Attention Deficit Hyperactivity Disorder (ADHD) is the most common behavioral disorder in childhood, and is estimated to affect three to five percent of people in the United States, both children and adults. Treatment typically involves a combination of behavior modification, educational interventions, and medication. There are a variety of medications available for treatment of ADHD; the most frequently prescribed drugs are stimulants or antidepressants. However, currently there is no way to tell in advance which medication will be most helpful for a particular individual.
The inventors have identified haplotypes of latrophilin 3 (LPHN3) that increase susceptibility for development of ADHD. LPHN3 is a G-protein coupled receptor that is specifically expressed in the brain’s mesolimbic system, which is associated with ADHD. The invention describes methods of identifying LPHN3 haplotypes in an individual for determining susceptibility for development of ADHD. Identification of LPHN3 haplotypes in an ADHD-affected individual may also make possible individualized drug treatment plans.
Identify individuals with enhanced susceptibility for ADHD
Use LPHN3 haplotype information to design individualized treatments
Inventors: Maximilian Muenke (NHGRI) Mauricio Arcos-Burgos (NHGRI) F X Castellanos (NIMH)
Licensing Status: Available for exclusive or nonexclusive licensing.
Portfolios: Internal Medicine Internal Medicine - Diagnostics Central Nervous System Central Nervous System - Diagnostics
For Additional Information Please Contact: Charlene Sydnor Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-4689 Fax: 301-402-0220